A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2015
At a glance
- Drugs MK 0429 (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 03 Nov 2009 Actual patient number (29) added as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.